Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) is a clinical-stage synthetic biology company focused on developing gene circuit medicines for oncology and other serious diseases. The company entered the public markets in 2022 through a de-SPAC business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS), a blank-check vehicle organized in the life sciences sector. Senti's platform applies proprietary gene circuit technology to engineer more selective next-generation cell and gene therapies. In September 2026, the company filed a preliminary proxy statement amendment (Form PRER14A) with the Securities and Exchange Commission, signaling a pending shareholder vote on a corporate matter. For the full filing record, transaction history, and real-time SPAC analytics on SNTI, sign up for complete data access on SpacDesk.